Jonathan L. Kaufman

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

Jens G. Lohr, Petar Stojanov, Scott L. Carter et al. · Cancer Cell · 2014 · 988 citations · Full text

Hematological Malignancy, Disease Heterogeneity, Widespread Genetic Heterogeneity +7

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Paul G. Richardson, Edie Weller, Sagar Lonial et al. · Blood · 2010 · 855 citations · Full text

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Jesús F. San Miguel, Vânia Hungria, Sung‐Soo Yoon et al. · The Lancet Oncology · 2014 · 781 citations

Hematological Malignancy, Double-blind Phase 3, Medicine +9

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

John F. DiPersio, Edward A. Stadtmauer, Auayporn Nademanee et al. · Blood · 2009 · 773 citations · Full text

Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth

Taro Hitosugi, Sumin Kang, Matthew G. Vander Heiden et al. · Science Signaling · 2009 · 772 citations · Full text